Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.26924 http://scihub22266oqcxt.onion/10.1002/jmv.26924 33675239!ä!33675239 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2021 ; 93 (7): 4054-4057 Nephropedia Template TP {{tp|p=33675239|t=2021. Nucleoside-modified messenger RNA COVID-19 vaccine platform |pdf=|usr=}}{{33675239}} gab.com Text Nucleoside-modified messenger RNA COVID-19 vaccine platform JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=33675239 #FOAvip On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic; from that date, the vaccine race has begun, and many technology platforms to develop a specific and effective COVID-19 vaccine have been launched in several clinical trials (protein subunit, RNA-based, DNA-based, replicating viral vector, nonreplicating viral vector, inactivated virus, live attenuated virus, and virus-like particle). Among the next-generation strategies, nucleoside-modified messenger RNA vaccines appear the most attractive, not only to counteract emerging pathogens but also for the possible applications in regenerative medicine and cancer therapy. However, exactly as all innovative drugs, they deserve careful pharmacovigilance in the short and long term. Twit Text FOAVip Nucleoside-modified messenger RNA COVID-19 vaccine platform ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=33675239 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33675239 #FOAvip English Wikipedia <ref>{{Cite pmid|33675239}}</ref> Nucleoside-modified messenger RNA COVID-19 vaccine platform #MMPMID33675239 Roncati L; Corsi L J Med Virol 2021[Jul]; 93 (7): 4054-4057 PMID33675239show ga On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic; from that date, the vaccine race has begun, and many technology platforms to develop a specific and effective COVID-19 vaccine have been launched in several clinical trials (protein subunit, RNA-based, DNA-based, replicating viral vector, nonreplicating viral vector, inactivated virus, live attenuated virus, and virus-like particle). Among the next-generation strategies, nucleoside-modified messenger RNA vaccines appear the most attractive, not only to counteract emerging pathogens but also for the possible applications in regenerative medicine and cancer therapy. However, exactly as all innovative drugs, they deserve careful pharmacovigilance in the short and long term. |*COVID-19 Vaccines/administration & dosage/adverse effects/immunology[MESH] |*Vaccines, Synthetic/administration & dosage/adverse effects/immunology[MESH] |2019-nCoV Vaccine mRNA-1273[MESH] |BNT162 Vaccine[MESH] |COVID-19/*prevention & control[MESH] |Humans[MESH] |Hypersensitivity/etiology[MESH] |Liposomes/adverse effects[MESH] |Nanoparticles/adverse effects[MESH] |Nucleosides[MESH] |Pandemics/prevention & control[MESH] |Pharmacovigilance[MESH] |Polyethylene Glycols/adverse effects[MESH] |RNA, Messenger/chemistry[MESH]Nucleoside-modified messenger RNA COVID-19 vaccine platform (epmc).pdf DeepDyve Pubget Overpricing